Trial Profile
Study of the combination of TACE with Apatinib in Patients with Hepatocellular Carcinoma Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 Mar 2017 New trial record